Navigation Links
Cylex(TM) Awarded New CPT Code For Its ImmuKnow(R) Assay
Date:1/12/2010

COLUMBIA, Md., Jan. 12 /PRNewswire/ -- Cylex Incorporated® announced today that the American Medical Association (AMA) CPT Editorial Panel approved the creation of new CPT coding based on the uniqueness, clinical value and widespread use of ImmuKnow, and the fact that existing CPT codes insufficiently captured all steps and costs of testing.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100112/NE34738LOGO )

In an effort to keep customers informed of these changes, the following new information is now available:

  • ImmuKnow is mapped to CPT Code: 86352, "Cellular function assay involving stimulation (e.g., mitogen or antigen) and detection of a biomarker (e.g., ATP)"

"We are very pleased by the decision of the AMA to recognize the value of ImmuKnow as a biomarker that provides valuable insight for individualized patient management by establishing a unique CPT code," said President, CEO and Chairman Brad L. Stewart. "We look forward to assisting clinicians with continuing to expand the implementation of ImmuKnow as standard of care in more effectively managing their patients' immunosuppression."

ImmuKnow is a biomarker of immune function that complements immunomodulatory therapy and helps physicians and other healthcare professionals more effectively manage immunosuppression in posttransplant patients, thereby reducing the risks of infection and rejection by:

  • Providing a global marker of immune function and response to immunosuppression at the cellular level
  • Detecting changes in CD4 cell ATP production
  • Helping to define a range of stable immune function for each patient
  • Providing critical, actionable information on an ongoing, individual basis when used longitudinally (in combination with other routine monitoring tests)

ImmuKnow is the FDA-cleared assay that tracks changes in global immune function over time.

*CPT = Current Procedural Terminology

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow assay is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. ImmuKnow is increasingly being adopted at organ transplant centers throughout the United States and abroad.

About Cylex, Inc.

Cylex is the commercial global life sciences company leading the development and manufacture of in vitro diagnostic assays that measure cellular immune function. The Company's unique technology detects cell-mediated immunity, which presents an exciting opportunity for development of additional assays for diseases, and companion diagnostics for treatments, that affect the immune system. ImmuKnow, its first commercial product, is an FDA-cleared, noninvasive biomarker of immune function which is utilized by clinicians to more effectively manage and optimize immunosuppression in organ transplant patients. Cylex is a Technology Fast 500™ award winner for 2009, Deloitte LLP's ranking of 500 of the fastest growing technology companies in North America. The Company is based in Columbia, MD USA.

SOURCE Cylex, Inc.

RELATED LINKS
http://www.cylex.net

'/>"/>

SOURCE Cylex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. LSUHSC awarded multi-million dollar grant to reduce pneumonia
2. K-State plant pathology professor awarded international professorship for Latin America
3. Penn, Georgia collaboration awarded $14.6 million to expand pathogen database
4. Air Force Center of Excellence awarded in nanostructures and improved cognition
5. Stanford researchers awarded $6.27 million to study energy efficiency and human behavior
6. University of Miami facility awarded prestigious LEED Green Building Certification
7. Professor Suzanne Cory awarded 2009 Pearl Meister Greengard Prize
8. UNC awarded $6.2 million renewal grant by NIH Rare Diseases Research Network
9. VBI awarded $27 million from NIH to support infectious disease research
10. UNC awarded Cancer Genome Atlas grant
11. 2 neuroscientists from Cold Spring Harbor Laboratory awarded transformative NIH grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology: